Dermatology Life Quality Index in Patients with Moderate-to-Severe Plaque Psoriasis Treated with Brodalumab or Ustekinumab

INTRODUCTION: Targeted biological therapies for psoriasis have resulted in significant benefits, with therapeutic goals such as clear or almost clear skin accompanied by improvements in health-related quality of life (HRQoL). The objective of this study was to compare the effects of 52 weeks of trea...

Descripción completa

Detalles Bibliográficos
Autores principales: Lambert, Jo, Hansen, Jes Birger, Sohrt, Anne, Puig, Luis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2021
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322208/
https://www.ncbi.nlm.nih.gov/pubmed/33988818
http://dx.doi.org/10.1007/s13555-021-00545-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8322208/
https://www.ncbi.nlm.nih.gov/pubmed/33988818
http://dx.doi.org/10.1007/s13555-021-00545-5

Ejemplares similares